Gadag Shivaprasad, Sinha Shristi, Nayak Yogendra, Garg Sanjay, Nayak Usha Y
Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal 576104, India.
Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal 576104, India.
Pharmaceutics. 2020 Jun 8;12(6):524. doi: 10.3390/pharmaceutics12060524.
Breast cancer has become one of the biggest concerns for oncologists in the past few decades because of its unpredictable etiopathology and nonavailability of personalized translational medicine. The number of women getting affected by breast cancer has increased dramatically, owing to lifestyle and environmental changes. Besides, the development of multidrug resistance has become a challenge in the therapeutic management of breast cancer. Studies reveal that the use of monotherapy is not effective in the management of breast cancer due to high toxicity and the development of resistance. Combination therapies, such as radiation therapy with adjuvant therapy, endocrine therapy with chemotherapy, and targeted therapy with immunotherapy, are found to be effective. Thus, multimodal and combination treatments, along with nanomedicine, have emerged as a promising strategy with minimum side effects and drug resistance. In this review, we emphasize the multimodal approaches and recent advancements in breast cancer treatment modalities, giving importance to the current data on clinical trials. The novel treatment approach by targeted therapy, according to type, such as luminal, HER2 positive, and triple-negative breast cancer, are discussed. Further, passive and active targeting technologies, including nanoparticles, bioconjugate systems, stimuli-responsive, and nucleic acid delivery systems, including siRNA and aptamer, are explained. The recent research exploring the role of nanomedicine in combination therapy and the possible use of artificial intelligence in breast cancer therapy is also discussed herein. The complexity and dynamism of disease changes require the constant upgrading of knowledge, and innovation is essential for future drug development for treating breast cancer.
在过去几十年里,乳腺癌因其不可预测的病因病理以及个性化转化医学的缺乏,已成为肿瘤学家最为关注的问题之一。由于生活方式和环境的变化,患乳腺癌的女性人数急剧增加。此外,多药耐药性的出现已成为乳腺癌治疗管理中的一项挑战。研究表明,由于高毒性和耐药性的产生,单一疗法在乳腺癌治疗中效果不佳。放射治疗与辅助治疗、内分泌治疗与化疗、靶向治疗与免疫治疗等联合疗法被发现是有效的。因此,多模式和联合治疗以及纳米医学已成为一种有前景的策略,副作用和耐药性最小。在本综述中,我们强调乳腺癌治疗方式的多模式方法和最新进展,重视当前临床试验的数据。讨论了针对不同类型乳腺癌(如管腔型、HER2阳性型和三阴性乳腺癌)的靶向治疗新方法。此外,还解释了被动和主动靶向技术,包括纳米颗粒、生物共轭系统、刺激响应系统以及核酸递送系统(包括siRNA和适体)。本文还讨论了探索纳米医学在联合治疗中的作用以及人工智能在乳腺癌治疗中可能应用的最新研究。疾病变化的复杂性和动态性要求知识不断更新,创新对于未来乳腺癌治疗药物的开发至关重要。